Estrella Immunopharma (ESLAW) Competitors $0.05 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ESLAW vs. ATNFW, SXTPW, DRTSW, APLMW, BCTXW, CDIOW, CELUW, CEROW, CINGW, and CLNNWShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Celularity (CELUW), CERo Therapeutics (CEROW), Cingulate (CINGW), and Clene (CLNNW). These companies are all part of the "biotechnology" industry. Estrella Immunopharma vs. Its Competitors 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Celularity CERo Therapeutics Cingulate Clene 180 Life Sciences (NASDAQ:ATNFW) and Estrella Immunopharma (NASDAQ:ESLAW) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Does the media prefer ATNFW or ESLAW? In the previous week, Estrella Immunopharma had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for 180 Life Sciences. Estrella Immunopharma's average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Estrella Immunopharma Very Positive Which has stronger earnings & valuation, ATNFW or ESLAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AEstrella ImmunopharmaN/AN/AN/AN/AN/A Is ATNFW or ESLAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Estrella Immunopharma N/A N/A N/A SummaryEstrella Immunopharma beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLAW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLAW vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$153.68M$5.84B$10.14BDividend YieldN/A3.78%5.68%4.60%P/E RatioN/A41.0875.4125.98Price / SalesN/A4,942.15515.81181.13Price / CashN/A13.1937.5660.44Price / BookN/A103.7512.156.29Net IncomeN/A-$90.99M$3.29B$271.07M7 Day PerformanceN/A2.86%0.74%3.87%1 Month PerformanceN/A21.20%5.00%5.49%1 Year PerformanceN/A526.77%62.55%25.86% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAWEstrella ImmunopharmaN/A$0.05flatN/AN/A$0.00N/A0.00N/APositive NewsATNFW180 Life SciencesN/A$0.10-43.6%N/A+1,189.8%$0.00N/A0.007High Trading VolumeSXTPW60 Degrees PharmaceuticalsN/A$0.05-5.7%N/AN/A$0.00$641.41K0.002Positive NewsGap DownDRTSWAlpha Tau MedicalN/A$0.30+0.7%N/AN/A$0.00N/A0.0080Gap DownAPLMWApollomicsN/A$0.02-3.2%N/A+68.9%$0.00N/A0.0059Short Interest ↓Gap DownBCTXWBriaCell TherapeuticsN/A$0.03+4.6%N/A-84.4%$0.00N/A0.008Short Interest ↑Gap DownCDIOWCardio DiagnosticsN/A$0.02-4.0%N/A-39.6%$0.00$19.51K0.007Short Interest ↓Gap DownCELUWCelularityN/A$0.05+10.9%N/A+173.2%$0.00$44.59M0.00220Gap DownCEROWCERo TherapeuticsN/A$0.01+1.4%N/A+40.0%$0.00N/A0.008Gap DownCINGWCingulateN/A$0.05-4.0%N/A-24.4%$0.00N/A0.0020CLNNWCleneN/A$0.03-4.4%N/A-48.2%$0.00$286K0.00100Gap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 60 Degrees Pharmaceuticals Competitors Alpha Tau Medical Competitors Apollomics Competitors BriaCell Therapeutics Competitors Cardio Diagnostics Competitors Celularity Competitors CERo Therapeutics Competitors Cingulate Competitors Clene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLAW) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
